Kanyos Bio is a Cambridge, MA-based biotechnology company developing antigen-specific immune tolerance therapeutics for autoimmune diseases, with a focus on type 1 diabetes and celiac disease. Established in 2015 as a collaboration between Anokion SA and Astellas Pharma, Kanyos leveraged Anokion's red-blood-cell-targeted antigen platform (originating at EPFL) to advance clinical candidates including KAN-101 for celiac disease. The company was acquired by parent Anokion in September 2019, consolidating its programs back into Anokion's pipeline alongside Anokion's lead multiple sclerosis candidate.
Kanyos Bio has been acquired
This company is no longer available on our private secondary market.
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2015
Employees
1–10
Total Funding
$16.4M
1 rounds
Total raised $16.4M across 1 rounds
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Last updated 06-25-2026
Latest Round
Type
Series A
Date
June 12, 2015
Amount
$16.4M
Valuation
—
Lead Investors
Kristen Lorentz
Co-Founder
Oscar Buset
Co-Founder
Competitor list is illustrative and may be incomplete, stale, or erroneous.
Anokion SA
Swiss parent company developing the same antigen-specific immune tolerance platform; acquired Kanyos in 2019.
Cour Pharmaceuticals
Develops antigen-specific immune tolerance nanoparticle therapies for autoimmune diseases including celiac disease and type 1 diabetes.
Provention Bio
Developer of teplizumab (Tzield) for delaying type 1 diabetes; acquired by Sanofi in 2023.
ImmunoMolecular Therapeutics
Clinical-stage biotech developing antigen-specific therapies for type 1 diabetes.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.